DOI: 10.36347/sjams.2020.v08i10.003

Pages: 2225-2230

Objective: In this study our main goal is to assess antiproteinuric effects of Doxycycline in patients with diabetic nephropathy. Method: This is a prospective interventional study and conducted at the Department of Nephrology in DMCH.The study included 60 clinically proven adult patients of DN. All patients were on optimal doses of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for 2 months before the study. The patients were divided into two groups named control (group I, n = 30) and intervention group (group II, n = 30). Control group patients were maintained on optimal doses of ACEIs or ARBs, whereas intervention group patients received Doxycycline (100 mg/day) for a period of 3 months in addition to ACEIs or ARBs. Data were collected at month 0 and at month 1 at month 3. Results: The study result revealed that before intervention, the mean basal levels of 24 hours proteinuria was 2.2 ± 1.3g/day for Group I and 2.7 ± 1.42 g/day for Group II. P value is not significant in both group at baseline (p=0.2). Adequate glycemic control was achieved with insulin, oral hypoglycemic agents or both in all the patients. It reduced to 2.0 ± 1.2g/day for Group I and 2.5± 1.3g/day for Group II, at the end of 1 month. At the end of 3 months, a significant decline of proteinuria was observed in both the groups. In Group I it had a mean of 1.95 ± 1.2g/day, whereas it was 1.25± 0.78g/day in Group II. A statistically significant difference existed between the control and intervention groups (p < 0.05), at 3 months. Conclusion: Doxycycline has significantly reduces proteinuria in diabetic nephropathy patients.